A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacyof Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected with Chronic HCV for Use in the Peri-Operative Liver Transplantation Setting
||Male and Female Patients
|U.S. Govt. ID:
||Eric Przybyszewski: 212-305-3839 / email@example.com
The purpose of this study is to see if the study drug Harvoni given for 4 weeks immediately after liver transplantation is safe and able to clear the Hepatitis C virus (HCV) from the body. This study will test a drug named Harvoni for the treatment of chronic genotype 1 or 4 Hepatitis C Virus (HCV) in peri-operative liver transplant patients. Harvoni (LDV/SOF FDC) is approved in the United States for treatment of chronic genotype 1 HCV infection.in adult patients but not for genotype 4. It is still being tested in research studies for genotype 4.
This study is closed
Elizabeth Verna, MD
|Do you currently suffer from chronic HCV infection?
|Are you currently on the liver transplantation wait list?